Peptides for dementia FAQ

Cerebrolysin's peptide fractions degrade in the gastrointestinal tract, which is why every clinical trial uses intravenous infusion. Oral cerebrolysin would be enzymatically cleaved into constituent amino acids before reaching systemic circulation—eliminating the intact peptide sequences responsible for neurotrophic receptor binding. No oral formulation has demonstrated bioequivalence to IV cerebrolysin in pharmacokinetic studies.

No peptide has been studied in primary prevention—meaning cognitively healthy individuals using peptides to reduce future dementia risk. All cerebrolysin trials enrolled patients with diagnosed Alzheimer's or vascular dementia; no trial has followed healthy adults for decades to measure incident dementia rates. Using investigational peptides preventively means accepting zero evidence of benefit and unknown long-term safety profiles.

You'll wait indefinitely unless a research institution or pharmaceutical company sponsors formal trials. Dihexa synthesis is straightforward, but moving from rodent efficacy to Phase I human trials requires regulatory approval, institutional review board oversight, and funding—none of which currently exists for this compound. Using dihexa now means participating in uncontrolled self-experimentation with unknown risks.

Combining peptides with non-overlapping mechanisms (e.g., Cerebrolysin for neurotrophic support + Thymalin for immune modulation) theoretically addresses multiple pathways of neurodegeneration. The limitation: no human studies have tested combination protocols. Drug-drug interactions, receptor desensitisation, and cumulative metabolic load are all unknown variables. Stacking peptides without clinical precedent is high-risk experimentation. If exploring combinations, do so under medical supervision with baseline and follow-up cognitive and metabolic testing.

Peptide quality varies dramatically across suppliers. Lyophilised peptides should arrive as white or off-white powder in vacuum-sealed vials. Discoloration (yellow, brown), clumping, or moisture inside the vial indicates degradation or contamination. Legitimate research-grade suppliers provide third-party certificates of analysis (COA) showing purity via HPLC and mass spectrometry. If the supplier cannot provide a COA with batch number matching your vial, do not use the product. Temperature excursions during shipping (especially for peptides requiring cold storage like Cerebrolysin) denature the protein structure irreversibly. A compromised peptide is not 'less effective,' it is biologically inert.

No peptide has been studied in truly asymptomatic populations for primary prevention of dementia. The clinical trials for Cerebrolysin enrolled patients with existing vascular dementia or mild cognitive impairment. Not cognitively healthy individuals. Using peptides preventively means operating outside the evidence base. The mechanistic rationale exists (neurotrophic support, inflammation reduction, mitochondrial enhancement), but the risk-benefit calculation is speculative. If prevention is the goal, addressing modifiable risk factors. Hypertension, insulin resistance, chronic inflammation. Has stronger evidence than any peptide protocol.